Artiva Biotherapeutics (ARTV)

• Market cap: $102M
• 1 day: -6.27%
• 5 days: -18.96%
• 1 month: -6.94%
• 3 months: -1.27%
• 6 months: 30.54%
• Year to date: -8.04%
• 1 year: -27.96%
• 5 years: -67.58%
• 10 years: -67.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Employees: 106